Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes zipalertinib in adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC that has specific mutations in the EGFR gene called exon 20 insertions and other uncommon mutations. This Phase 2b study includes participants with different prior treatment histories and brain metastases to understand how zipalertinib works in these groups. The study also explores possible interactions between zipalertinib and other drugs and aims to identify the best dose for treatment. Participants are divided into four main groups based on their mutation type and treatment history. They receive zipalertinib orally twice daily continuously until disease progression or other reasons for stopping. Additional substudies enroll participants to evaluate drug interactions using special probe medications and to optimize dosing by randomly assigning participants to different dose groups. The dosing cycles last 21 days, and treatments continue as long as criteria are met. Throughout the study, participants undergo regular assessments including tumor measurements, brain imaging for those with brain metastases, heart monitoring with ECG and scans, laboratory tests, and evaluation of side effects. Researchers measure outcomes such as tumor response rates, disease control, progression-free survival, and overall survival for up to two years. Safety is closely monitored by tracking adverse events and changes in vital signs and organ function. Participants remain under observation during treatment and follow-up periods until study completion.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new blood test called Syantra DX Breast Cancer to detect breast cancer early. This test measures gene expression signatures in whole blood using a special multi-biomarker panel and proprietary algorithms to classify samples as positive or negative for breast cancer. The study aims to validate this method in a screening population by comparing test results with diagnostic imaging scores, biopsy outcomes, and subject characteristics to improve early cancer identification. The study includes women aged 30 to 75 years who are undergoing screening mammograms. Participants provide blood samples around the time of their mammogram, including women with abnormal mammograms classified under specific scoring systems and those with normal or benign results. Blood samples are collected before biopsy in women with abnormal mammograms and processed anonymously for RNA extraction and analysis. An optional additional research component allows participants to consent to further investigations on stored blood materials. Participants provide informed consent and give blood samples for testing. The study collects clinical data including imaging scores and pathology results, which are compared to the blood test outcomes. The main measure is the tests sensitivity and specificity in detecting breast cancer, with data recorded about 18 months from enrollment. Researchers will also assess the tests ability to predict molecular subtypes and adjust methodology based on prospective samples. The study is conducted under blind conditions to ensure unbiased analysis.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of targeted blood-brain barrier opening using the Exablate Model 4000 Type 2 device in patients with brain metastases from non-small cell lung cancer NSCLC. This study focuses on patients receiving planned FDA-approved immune checkpoint inhibitor ICI systemic therapy for their primary NSCLC. The goal is to determine if adding the Exablate treatment improves the objective response rate of brain metastases compared to standard care alone. Participants are divided into two groups one receiving the Exablate blood-brain barrier opening combined with ICI therapy, and a control group receiving only the standard ICI systemic therapy. Immunotherapy is given every three weeks for six cycles according to approved guidelines. The Exablate procedure involves opening the blood-brain barrier on the day of ICI infusion to target brain metastases. The study is conducted at multiple centers across the US and lasts for up to six months of follow-up after treatment. During the trial, participants undergo MRI scans to monitor tumor lesions in the brain and assessments of adverse events. Researchers evaluate tumor responses using neuro-oncology criteria and track the time to response. Safety is closely monitored throughout the six-month period. Participants provide informed consent and are assessed for eligibility before joining. The study aims to provide detailed information on treatment effects and safety for patients with NSCLC brain metastases receiving immunotherapy.
Actively Recruiting
Researchers are studying the safety, effectiveness, and how the body processes the investigational drug WAL0921 in adults with various glomerular kidney diseases and proteinuria. These include diabetic nephropathy and rare conditions such as primary focal segmental glomerulosclerosis, treatment-resistant minimal change disease, primary immunoglobulin A nephropathy, and primary membranous nephropathy. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to evaluate WAL0921 compared to a placebo. Participants will be randomly assigned to receive either the investigational drug WAL0921 or a placebo through an intravenous infusion every two weeks for a total of seven infusions. The study includes a treatment period followed by a 24-week follow-up after the last infusion to monitor participants. The treatments are given in parallel groups to compare their effects and safety. During the study, participants will undergo regular assessments including monitoring for adverse events from the start through Week 36. Researchers will also measure changes in albuminuria, proteinuria, and kidney function markers such as estimated glomerular filtration rate over 24 weeks. These evaluations help determine how the drug affects kidney disease markers and overall safety. The total participation time includes treatment and follow-up periods lasting several months.
Actively Recruiting
Researchers are evaluating the Force Feedback function of the da Vinci 5 dV5 robotic surgical system to understand its impact on surgical skill learning and safety during robot-assisted radical prostatectomy RARP in patients with localized prostate cancer. This prospective single-center clinical trial involves 60 male patients and aims to provide objective evidence on how tactile feedback may improve surgical precision and reduce tissue injury compared to previous systems lacking this feature. The study randomly assigns the Force Feedback function to be ON or OFF during each surgery, with two surgeons one expert and one trainee each performing 30 RARP cases. The Force Feedback ON mode provides real-time tactile sensations through robotic instruments, allowing surgeons to feel tissue resistance and potentially improve control. The OFF mode relies solely on visual cues. The seminal vesicle dissection step is specifically assessed for traction force and instrument movement. Participants will undergo detailed intraoperative monitoring, including measurement of traction force, instrument path length, and surgical performance metrics like operative time and clutch counts. Safety is closely monitored through recording complications, blood loss, and patient-reported outcomes related to urinary and sexual function. All surgeries are video-recorded and analyzed to assess precision and learning curves, with follow-up continuing up to the studys completion in 2027.
Actively Recruiting
This research aims to compare symptoms in patients with proximal gastric and gastroesophageal junction cancers who undergo two types of minimally invasive surgeries proximal gastrectomy MIPG and total gastrectomy MITG. The study focuses on evaluating short-term appetite differences and how these may affect nutritional status and body weight after surgery. It also investigates patient-reported outcomes and safety measures related to these surgical procedures. Participants will complete questionnaires about their health, appetite, and quality of life before surgery and then at 1, 3, 6, and 12 months after surgery. The study collects data using the MD Anderson Symptom Inventory Gastrointestinal Cancer Module with additional experimental questions and measures fasting ghrelin levels to understand appetite changes. The study also looks at factors influencing quality of life, surgical safety, and cancer outcomes after each surgery type. During the study, participants will be asked to complete brief questionnaires taking about 3 to 5 minutes each time. These assessments occur before surgery and during follow-up visits up to one year after surgery. Researchers will analyze questionnaire responses and biological markers to measure symptoms, appetite, and quality of life. The study is observational, and participants will be monitored without additional interventions beyond standard care.